No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 36.9x · 10Y median 9.4x · 70th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:07.457Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Opus Genetics, Inc. (IRD) stock was $4.40 as of Oct 6, 2026, 10:00 AM EDT, up 0.46% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +132.0%
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology.
Biotechnology · Durham, NC
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.14
Revenue Est.
$1.54M
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.16
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IRD | $363.29M | $4.40 | +0.46% | +132.04% | N/A | N/A | N/A |
| 2FENC | $362.03M | $10.42 | -1.86% | +7.45% | +2.45% | N/A | vs IRD |
| 3ENTA | $360.14M | $12.38 | -1.71% | +21.86% | -26.94% | -7.11% | vs IRD |
| 4EMBC | $353.59M | $5.96 | +1.36% | -57.42% | N/A | N/A | vs IRD |
| 5CGC | $373.86M | $0.89 | +0.12% | -35.30% | -63.36% | -31.35% | vs IRD |
| 6AGEN | $351.05M | $8.43 | -3.44% | +110.12% | -40.10% | -24.61% | vs IRD |
N/A
$755000.00
vs Estimate
$2.63M
Consensus Rating
Based on 17 analysts
Average Price Target
$13.00
+195.5% upside
Low
$8.00
Current
$4.40
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.15 | $-0.08 | 10 |
| Quarter ending Dec 2026 | $-0.21 | $-0.09 | $0.21 | 10 |
| Quarter ending Mar 2027 | $-0.32 | $-0.16 | $0.02 | 8 |
| Quarter ending Jun 2027 | $-0.33 | $-0.17 | $0.02 | 8 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.30 | $-1.04 | $-0.29 | 13 |
| FY 2027 | $-1.24 | $-0.70 | $-0.40 | 12 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $504086.00 | $1.54M | $4.41M | 12 |
| Quarter ending Dec 2026 | $809544.00 | $6.86M | $12.14M | 12 |
| Quarter ending Mar 2027 | $198113.00 | $1.68M | $2.97M | 6 |
| Quarter ending Jun 2027 | $198113.00 | $1.68M | $2.97M | 6 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.03M | $11.54M | $20.53M | 14 |
| FY 2027 | $1.50M | $11.91M | $24.20M | 13 |
